Navigation Links
Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
Date:1/31/2008

SAN MATEO, Calif., Jan. 31 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. today announced it has entered into manufacturing agreements with Albemarle Corporation and Patheon Inc. The agreements provide for the large-scale clinical production of Varespladib (A-002), which is expected to be necessary in preparation for Anthera's Phase III clinical trials and planned New Drug Application submission to the Food and Drug Administration. Varespladib is Anthera's oral drug candidate for the treatment of cardiovascular disease.

Anthera believes the agreements position the company to:

-- Secure a cost-effective, long-term supply of Varespladib active

pharmaceutical ingredient (API) and tablets.

-- Quickly scale current manufacturing efforts to meet production

requirements, potentially accelerating Varespladib's time-to-market.

-- Reduce manufacturing related risks to the Varespladib clinical program.

-- Ensure a cost-effective transition to registration and commercial

production.

Building on the work done by Anthera's licensor, Eli Lilly, Albemarle will be responsible for process optimization and manufacture of cGMP quantities of the API. Patheon will be responsible for finished tablet production. The agreement also provides an option for the commercial production of Varespladib in the future. Financial terms were not disclosed.

"These agreements with Albemarle and Patheon provide Anthera with key supply chain resources for the manufacture of Varespladib," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "We are pleased to have secured outstanding technical organizations with significant commercial expertise that will contribute to the future success of the Varespladib program."

"We're delighted that Anthera has selected Albemarle as its API manufacturing supplier for its next phase of development," said David Clary, Albemarle Division V
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
6. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
7. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
8. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
11. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 With ... cytometry is experiencing a rise in active partnerships. ... in underdeveloped nations to quantitate CD4 cell markers ... Logo - http://photos.prnewswire.com/prnh/20150831/262206LOGO ... the Global Flow Cytometry Market ( http://www.frost.com/nf0e ), ...
(Date:8/31/2015)...  The departments of Drug and Alcohol Programs (DDAP) ... 90 to raise awareness for International Overdose Awareness Day ... Pennsylvania and help more Pennsylvanians with substance ... the Building Bridges to Recovery initiative. ... to a disease that is fully treatable, if given ...
(Date:8/31/2015)... Mich. , Aug. 31, 2015  Diplomat Pharmacy, Inc. ... has announced that Phil Hagerman , Chairman & CEO, ... upcoming investor conferences. Mr. Hagerman and Mr. ... Healthcare Conference in Boston on Wednesday, ... Hagerman and Mr. Whelan are also scheduled to participate in ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Diplomat to Participate in Upcoming Investor Conferences 2
... -- Keryx,Biopharmaceuticals, Inc. today announced that abstracts ... selected for,publication or presentation during the poster ... American Diabetes Association (ADA) 67th,Annual Scientific Sessions ... in Chicago, Illinois. , Copies of these ...
... 21, 2007 - The,PromegaExpress(TM) on-site stocking program just ... of on-site appliances. This,latest addition serves as great ... areas when space is at a premium,but immediate ... The,mid-sized cabinet can also be stacked with another ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois 2Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois 3Keryx Biopharmaceuticals, Inc. Announces Poster Presentations,Highlighting Mechanism of Action and Clinical Activity of,Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American,Diabetes Association 67th Scientific Sessions in Chicago, Illinois 4
(Date:8/31/2015)... Sierra Madre, CA (PRWEB) , ... August 31, ... ... partnered wound center management, recently opened registration for the company’s second Introduction to ... will be held October 15-18, 2015 aboard the Queen Mary Hotel in Long ...
(Date:8/31/2015)... ... August 31, 2015 , ... Women’s Excellence ... , Starting September 1st they are offering pre and postnatal fitness classes ... Body, Healthy Baby." , More information can be found at 248-601-6683. , Women’s ...
(Date:8/31/2015)... FL (PRWEB) , ... August 31, 2015 , ... The ... quality healthcare to Veterans residing across southwest Florida by hiring more doctors and nurses ... the list of expanded services. , In early July, Dr. Anthony Jabre was selected ...
(Date:8/31/2015)... ... August 31, 2015 , ... Garden State ... 2008, the result of a merger of five of the busiest urology practices ... could provide more cost-effective and higher quality care than they did individually. ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Dr. Paul ... “NJ Top Doc.” , At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders ... traumatic injuries to the entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis ...
Breaking Medicine News(10 mins):Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2
... Making preschool available to all children age three and ... say three Yale scholars who have won the 2008 ... change would improve the school-readiness of the nations young ... high school dropout rate, reduce crime and boost the ...
... study of young women with heart attacksVIRGO (Variation in ... patients)was recently launched at Yale School of Medicine with ... This is the first study to focus on this ... Health Associate Professor Judith Lichtman, co-principal investigator of the ...
... received a renewal of a $1.5 million grant from the ... abilities of elderly drivers. The study is the first of ... natural driving environments. , Under the direction of principal ... Memory Disorders Center at Rhode Island Hospital, 150 older drivers ...
... certify retailers, utilities, financial institutions, ... healthcare organizations and others, ATLANTA, Dec. 18 ... over 2,000 clients, has been,designated as a Qualified Security Assessor ... PCI Security Standards,Council, created by the five major credit card ...
... Urologists Have Performed 15 Different, ... Procedures Include,Single Port Nissen Fundoplication, Colectomy, Prostatectomy ... Novare Surgical Systems,announced the successful completion ... RealHand HD instruments. These ,hidden scar, procedures,require ...
... few years much ballyhooed lunch hour and weekend ... are expected to pursue more reliably effective approaches ... Spiegel, MD, chief of facial plastic and reconstructive ... Boston Medical Center, people are frustrated and ...
Cached Medicine News:Health News:Yale launches landmark VIRGO study of young women with heart disease 2Health News:SecureWorks Designated as a Qualified Security Assessor for PCI Audits 2Health News:Novare Announces Completion of 100th Single Port Laparoscopic Procedure Using RealHand(R) High Dexterity (HD) Instruments 2Health News:Novare Announces Completion of 100th Single Port Laparoscopic Procedure Using RealHand(R) High Dexterity (HD) Instruments 3Health News:Significant changes in plastic surgery expected in 2008 2Health News:Significant changes in plastic surgery expected in 2008 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: